KarenJeanFerranteMD

PubMed

• 41 citations
  Androgen Receptor Modulation Optimized for Response—Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7...
  Mary-Ellen Taplin, Emmanuel S. Antonarakis, Karen J. Ferrante, Kerry Horgan, Brent A. Blumenstein
  European Urology. 2019-12-01
• 58 citations
  Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer
  Bruce Montgomery, Mario A. Eisenberger, Matthew Rettig, Franklin Chu, Roberto Pili
  Clinical Cancer Research. 2016-03-15
• 8 citations
  A phase I and pharmacologic study of the matrix metalloproteinase inhibitor CP-471,358 in patients with advanced solid tumors.
  Andre S. T. Planting, Ate van der Gaast, Patrick Schöffski, Michele Bartkowski, C. Verheij
  Cancer Chemotherapy and Pharmacology. 2005-02-01

Journal Articles

• Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer  
  Montgomery B, Eisenberger MA, Rettig MB, Chu FM, Pili R, Stephenson J, Vogelzang NJ, Koletsky AJ, Nordquist LT, Edenfield WJ, Mamlouk K, Ferrante KJ, Taplin, ME, Clin. Cancer Res, 1/2/2015
• A Phase 1 and Pharmacologic Study of the Matrix Metalloproteinase Inhibitor CP-471,358 in Patients with Advanced Solid Tumors  
  Planting A, van der Gaast A, Schoffski P, Bartkowski M, Verheij C, Noe D, Ferrante K, Verweij J, Cancer Chemotherapy and Pharmacology, 1/1/2005
• A Phase 1 Open Label Study of the Farnesyltransferase Inhibitor CP-609,754 in Patients with Advanced Malignant Tumors  
  Moulder S, Mahany JJ, Lush R, Rocha-Lima C, Langevin M, Ferrante KJ, Bartkowski LM, Kajiji SM, Noe DA, Paillet S, Sullivan S, Clinical Cancer Research, 1/1/2004
• A Phase I Pharmacologic Study of OSI-774, An Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Advanced Solid Malignancies  
  Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C, Eckhardt SG, Tolcher A, Britten CD, Denis L, Ferrante K, Von Hoff DD, Silberman S, Rowinsky EK, J Clin Oncol, 1/1/2001
• Promising new developments in cancer chemotherapy  
  Ferrante K, Winograd B, Canetta R, Cancer Chemotherapy and Pharmacology, 1/1/1999
• A Phase II trial of 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma  
  Sanz-Altamira P, Ferrante K, Jenkins RL, Lewis WD, Huberman MS, Stuart KE, Cancer, 1/1/1998
• Treatment of hepatocellular carcinoma with transjugular intrahepatic portosystemic shunting and chemoembolization  
  Stuart K, Anastopolous H, Ferrante K, Gordon FD, Stokes K, Am J Gastroenterol, 1/1/1995
• The plasma corticosteroid profile in the adjuvant induced arthritic rat model  
  Belliveau JF, Tschaen DM, Ferrante KJ, O'Leary GP, Fed Eur Biochem Soc, 1/1/1982
• Join now to see all

Abstracts/Posters

• Clinical factors associated with AR-V7 detection in ARMOR3-SV, a randomized trial of galeterone (Gal) vs enzalutamide (Enz) in men with AR-V7+ metastatic castration-re...
  Taplin ME, Antonarakis ES, Ferrante KJ, Horgan K, Blumenstein B, Saad F, Luo J, de Bono J, ASCO Annual Meeting, 1/1/2017
• Galeterone in Treatment-naive Patients with Castration-resistant Prostate Cancer with C-terminal Androgen Receptor Loss: Results from ARMOR2.
  Taplin ME, Chu F, Cochran J, Ferrante K, Lipsitz D, Roberts J, Sartor O, Heath E, ASCO Annual Meeting, 1/1/2016
• Randomized, open-label, multicenter, controlled study of galeterone vs enzalutamide in men with metastatic castration-resistant prostate cancer (mCRPC) expressing AR-V...
  Antonarakis E, de Bono J, Ferrante K, Horgan K, Luo J, Saad F, Taplin ME, ASCO Annual Meeting, 1/1/2016
• Drug-Drug Interaction (DDI) Study to Assess the Effect of Oral Galeterone on the Pharmacokinetics (PK) of Oral Midazolam.
  Ferrante KJ, Sonnichsen D, Jacoby D, ASCO GU Annual Meeting, 1/1/2016
• Galeterone-Induced Degradation of the Androgen Receptor Involves Inhibition of a Deubiquitinating Enzyme.
  Dransfield DT, Namdev N, Jacoby D, Ferrante KJ, ASCO GU Annual Meeting, 1/1/2016
• Androgen Receptor Modulation Optimized for Response: Splice Variant (ARMOR3-SV)-Randomized, Open-label, Multicenter, Controlled Study of Galeterone vs Enzalutamide in ...
  Taplin ME, Antonarakis ES, Luo J, Dransfield DT, Ferrante K, De Bono JS, ASCO Annual Meeting, 1/1/2015
• Androgen Receptor Modulation Optimized for Response in Splice Variant (ARMOR3-SV): Randomized, Open-label, Multicenter, Controlled Study of Galeterone versus Enzalutam...
  Roberts J, Dhillon R, Dransfield DT, Mamlouk KK, Ferrante KJ, Genitourinary Cancers Symposium, 1/1/2015
• Androgen Receptor Modulation Optimized for Response: Splice Variant (ARMOR3-SV)-Randomized, Open-label, Multicenter, Controlled Study of Galeterone vs Enzalutamide in ...
  Taplin ME, Antonarakis ES, Dransfield DT, Ferrante KJ, De Bono JS, Genitourinary Cancers Symposium, 1/1/2015
• Identification of a Companion Diagnostic (CDx) that Utilizes Circulating Tumor Cells (CTCs) to Detect an Androgen Receptor Splice Variant (AR-V7) in Metastatic Castrat...
  Dransfield D.T., Jacoby D, Mamlouk K, Ferrante, K, Prostate Cancer Foundation, 1/1/2014
• A Phase I and Pharmacokinetic Study of the Farnesyl Transferase Inhibitor, CP-609, 754 in Patients with Advanced Solid Tumors.
  Lush R, Mahany J, Langevin M, Bartkowski M, Noe D, Ferrante K, Sullivan D, 13th NCI-EORTC AACR Symposium;, 1/1/2002
• A Phase I and biologic correlative study of an oral vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, CP-547,632, in patients (pts) wi...
  Tolcher T, Karp DD, O'Leary JJ, DeBono JS, Caulkins JD, Molpus K, Sutula K, Ferrante KJ, Gualberto A, Noe DA, Huberman M, Rowinsky EK, Healey D, Proc Am Soc Clin Onc, 1/1/2002
• Phase I and Pharmacokinetic (PK) Study of the Matrix Metalloproteinase Inhibitor (MMPI), CP-471,358 in Patients (pts) with Advanced Solid Tumors.
  Planting A, Schoffski P, Van Der Gaast A, Bartkowski M, Noe D, Ferrante K, Verweij J, Proc Am Soc Clin Onc, 1/1/2002
• Dose-Schedule-Finding, Pharmacokinetic (PK), Biologic, and Functional Imaging Studies of OSI-774, a Selective Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase I...
  Rowinsky E, Hammond L, Siu L, Jerabek P, Rizzo J, Denis L, Nemunatis J, Patnaik A, Eckhardt G, Tolcher A, Takimoto C, Ferrante K, Allen LF, Silberman S, Hidalgo M, Proc Am Soc Clin Onc, 1/1/2001
• A Phase II trial of the epidermal growth factor receptor (EGFR) Tyrosine Kinase Inhibitor OSI-774, Following Platinum-Based Chemotherapy, in Patients (pts) with Advanc...
  Perez-Soler R, Chachoua A, Huberman M, Karp D, Rigas J, Hammond L, Rowinsky E, Preston G, Ferrante KJ, Allen LF, Nadler PI, Bonomi P, Proc Am Soc Clin Onc, 1/1/2001
• Phase 2 Evaluation of OSI-774, a Potent Oral Antagonist of the EGFR TK in Patients with Advanced Ovarian Carcinoma.
  Finkler A, Gordon A, Crozier M, Edwards R, Figueroa J, Garcia N, Hainsworth J, Irwin D, Silberman S, Allen L, Ferrante K, Fisher D, Nadler P, Proc Am Soc Clin Onc, 1/1/2001
• Phase 2 Evaluation of OSI-774, a Potent Oral Antagonist of the EGFR-TK in Patients with Advanced Squamous Cell Carcinoma of the Head and Neck.
  Senzer N, Soulieres D, Siu L, Agarwala S, Vokes E, Hidalgo M, Silbeman S, Allen L, Ferrante K, Nadler P, Proc Am Soc Clin Onc, 1/1/2001
• FDG-PET Evaluation of patients treated with epidermal growth factor (EGFR) tyrosine kinase inhibitor, CP 358,774.
  Hammond LA, Denis LJ, Salman UA, Chintapalli K, Hidalgo M, Jeraback P, Patnaid A, Allen LF, Ferrante KJ, Carter WO, Kuhn J, Drengler R, Silbernam S, Rowinsky EK, 11th NCI-EORTC-AACR Symposium, 1/1/2000
• A Phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), CP-358,774, following platinum-based chemotherapy in patients (pts) wi...
  Bonomi P, Perez-Soler R, Chachoua A, Huberman M, Karp D, Rigas J, Hammond L, Rowinsky E, Preston G, Ferrante KJ, Allen LF, 11th NCI-EORTC-AACR Symposium, 1/1/2000
• A Phase II multi-center study of the epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI), CP-358,774, in patients (pts) with advanced squamous cell...
  Siu LL, Soulieres D, Senzer N, Agarwala S, Vokes E, Fisher D, Marsolais C, Ferrante KJ, Allen LF, 11th NCI-EORTC-AACR Symposium, 1/1/2000
• Phase I and Pharmacokinetic Study of BMS-184476, A New Taxane Analog, Given Weekly In Patients With Advanced Malignancies.
  Highley M, Sessa C, Hughes A, Ghielmini M, Plummer R, Bosch S, Calvert P, Calvert AH, Renard J, Sonnichsen D, Ferrante K, Gallant G, Proc Am Soc Clin Onc, 1/1/1999
• Phase I and Pharmacokinetic (PK) Study of BMS 184476, a Potent and Soluble Taxane Analog, as A 1-Hour Infusion Every 3 Weeks.
  Hidalgo M, Aylesworth C, Ferrante K, Weiss G, Britten C, Stephenson J, Johnson T, Smith L, Molpus K, LaCreta F, Kadow J, Healey D, Eckhard G, Von Hof D, Rowinsky E, Proc Am Soc Clin Onc, 1/1/1999
• Phase II study of 5-FU, leucovorin, and carboplatin in unresectable cholangiocarcinoma.
  Sanz-Altamira P, Huberman M, Ferrante K, Stuart K, Proc Am Soc Clin Onc, 1/1/1996
• Patient characteristics and prognostic variables among hepatoma patients at a single institution.
  Anand A, Ferrante K, Stuart K, Proc Am Soc Clin Onc, 1/1/1995
• Modulation of multidrug resistance to doxorubicin using tamoxifen in hepatocellular carcinoma.
  Stuart K, Campbell K, Ferrante K, Proc Am Soc Clin Onc, 1/1/1994
• Join now to see all

Lectures

• "Cancer management in the 90's, the latest trends" 
  Waltham, MA - 1/1/1995